Buprenorphine Extended-Release SC Injection Under Review Again for Opioid Use Disorder
The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021.
Diagnosis & Disease Information
DEA: “Rainbow Fentanyl” a Deliberate Tactic to Target Young People
Brightly colored versions of the synthetic opioid fentanyl are appearing across the US, according to the Drug Enforcement Administration (DEA). In a press statement, the Agency reported that the colorful fentanyl, dubbed “rainbow fentanyl”, has been seized in 18 different states and has been found in multiple forms, including pills, powder, and blocks that resemble…
Genetically Targeted Therapeutic Looks Promising for Alcohol Use Disorder
AD04 is a genetically targeted, serotonin-3 receptor antagonist that is believed to reduce alcohol intake by interfering with the dopamine reward system.
White House Releases Detailed Plan to Tackle the Overdose Epidemic
The Strategy focuses on 2 main drivers of the opioid epidemic: drug trafficking and untreated addiction.
FDA Issues Draft Guidance on Nonopioid Analgesic Drug Development
The FDA defines acute pain as pain, lasting up to 30 days, typically in response to some form of tissue injury, such as trauma or surgery.
Once-Weekly Levomethadone Fast Tracked for Opioid Use Disorder
LYN-014 is an investigational oral, once-weekly, ultra-long-acting, extended-release levomethadone capsule to treat opioid use disorder.
FDA: Dietary Supplements Containing Kratom Seized
The consumption of kratom can lead to serious medical outcomes.
- Loading...
Loading...
Loading... 
Loading...